Evidence map›Paper›PMID 41487145›Full record

ArticleJournal of pharmaceutical analysis2025

Unveiling optimal molecular features for hERG insights with automatic machine learning.

Congying Xu, Youjun Xu, Ziang Hu, Xinyi Zhao, Weixin Xie, Weiren Chen, Jianfeng Pei

Abstract read
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Congying XuCenter for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.
Youjun XuInfinite Intelligence Pharma, Beijing, 100083, China.
Ziang HuInfinite Intelligence Pharma, Beijing, 100083, China.
Xinyi ZhaoInfinite Intelligence Pharma, Beijing, 100083, China.
Weixin XieInterdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou, 350108, China.
Weiren ChenInfinite Intelligence Pharma, Beijing, 100083, China.
Jianfeng PeiCenter for Quantitative Biology, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We developed MaxQsaring, a novel universal framework integrating molecular descriptors, fingerprints, and deep-learning pretrained representations, to predict the properties of compounds. Applied to a case study of human ether-à-go-go-related gene (hERG) blockage prediction, MaxQsaring achieved state-of-the-art performance on two challenging external datasets through automatic optimal feature combinations, and successfully identified top 10 important interpretable features that could be used to model a high-accuracy decision tree. The models' predictions align well with empirical hERG optimization strategies, demonstrating their interpretability for practical utilities. Deep learning pre-trained representations have been demonstrated to exert a moderate influence on enhancing the performance of predictive models. Nevertheless, their impact on augmenting the generalizability of these models, particularly when applied to compounds possessing novel scaffolds, appears to be comparatively minimal. MaxQsaring excelled in the Therapeutics Data Commons (TDC) benchmarks, ranking first in 19 out of 22 tasks, showcasing its potential for universal accurate compound property prediction to facilitate a high success rate of early drug discovery, which is still a formidable challenge.

Indexed as

Automatic machine learningFeature combinationhERG blockage predictionPretrained representationsXGBoost

Identifiers

PMID41487145
PMCPMC12756696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.